The Pharmacy Times® Colorectal Cancer Resource Center is a comprehensive resource for clinical news and expert insights on cancers that start in the colon or the rectum.
March 25th 2024
The test’s sensitivity in distinguishing colorectal cancer, in combination with real-world adherence, showed its ability to detect cancer at a curable stage.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Advances in the Treatment of Metastatic Renal Cell Carcinoma: New Horizons in Targeted Therapies
1.0 Credit / Genitourinary Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Study: Multilevel Data Model Helps Estimate Likelihood of Delays in Cancer Treatment
August 24th 2023In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.
Read More
FDA Approves Bevacizumab Biosimilar for Six Types of Cancer
September 28th 2022Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More